Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

7.6K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

84.7K
Overview
84.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.2K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
The Tumor Microenvironment02:17

The Tumor Microenvironment

7.9K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

ILC2s shoot 4 making 13s.

Science immunology·2026
Same author

Broad screening of inflammation-associated proteins identifies serum CCL19 as a novel biomarker of disease activity in IgG4-related disease.

Annals of the rheumatic diseases·2026
Same author

Smart chains: Designer antibodies shaped by AI.

Science immunology·2025
Same author

A roadmap for defining "extrafollicular" B cell responses.

Immunity·2025
Same author

A LAGging kiss leaves T cells cold.

Science immunology·2025
Same author

Loss of B cell tolerance at the T2/T3a B cell transition is a convergent pathogenic mechanism in common variable immunodeficiency.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Feb 21, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.1K

JAKing up resistance to immunotherapy.

Faisal Alsufyani1, Shiv Pillai1

  • 1Ragon Institute of MGH, MIT and Harvard Department of Medicine, Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA 02139, USA.

Science Immunology
|October 8, 2017
PubMed
Summary

A CRISPR screen identified key genes and pathways that help cancer cells evade immunotherapy. This discovery offers new targets for improving cancer treatment effectiveness.

More Related Videos

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics
12:19

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Published on: June 7, 2024

2.1K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.6K

Related Experiment Videos

Last Updated: Feb 21, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.1K
Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics
12:19

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Published on: June 7, 2024

2.1K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.6K

Area of Science:

  • * Immunology and Cancer Biology: Investigating the complex interplay between the immune system and cancer development.
  • * Genetics and Genomics: Utilizing advanced genetic screening techniques to uncover novel biological mechanisms.

Background:

  • * Cancer immunotherapy has revolutionized treatment but faces challenges due to intrinsic or acquired resistance.
  • * Understanding the genetic basis of this resistance is crucial for developing more effective therapeutic strategies.

Purpose of the Study:

  • * To identify genes and molecular pathways that confer resistance to cancer immunotherapy using a novel screening approach.
  • * To provide a foundation for developing new combination therapies that overcome treatment resistance.

Main Methods:

  • * A two-cell type CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) screen was employed to systematically disrupt genes.
  • * The screen was designed to identify genetic alterations that promote survival or growth in the presence of immunotherapy.

Main Results:

  • * The screen successfully identified a set of genes and signaling pathways critically involved in mediating resistance to cancer immunotherapy.
  • * Specific genetic vulnerabilities were uncovered that, when targeted, could potentially re-sensitize tumors to immune attack.

Conclusions:

  • * This study provides a valuable genetic resource for understanding and overcoming cancer immunotherapy resistance.
  • * The identified genes and pathways represent promising targets for future therapeutic interventions aimed at enhancing immunotherapy efficacy.